Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00334802
Status:
COMPLETED
Last Update Posted:
2010-03-16
First Post:
2006-06-06
Brief Title:
Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Combination Study of LY188011 and Paclitaxel in Patients With MetastaticRecurrent Breast Cancer After Neo-adjuvantAdjuvant Chemotherapy With Anthracycline
Status:
COMPLETED
Status Verified Date:
2010-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate efficacy safety and PK of gemcitabine and paclitaxel combination in patients with metastatic breast cancer after adjuvantneo-adjuvant chemotherapy with anthracycline regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B9E-JE-MB22 | OTHER | Eli Lilly and Company | None |